Executioner caspases and CAD are essential for mutagenesis induced by TRAIL or vincristine

被引:30
作者
Miles, Mark A. [1 ]
Hawkins, Christine J. [1 ]
机构
[1] La Trobe Univ, La Trobe Inst Mol Sci, Dept Biochem & Genet, Bundoora, Vic 3086, Australia
关键词
APOPTOTIC DNA FRAGMENTATION; MLL BREAKPOINT CLUSTER; ACTIVATED DNASE; CELL-DEATH; TOPOISOMERASE-I; MITOTIC CATASTROPHE; MAMMALIAN-CELLS; SURVIVING CELLS; CANCER-THERAPY; ENDONUCLEASE-G;
D O I
10.1038/cddis.2017.454
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Chemotherapy drugs interfere with cellular processes to generate genotoxic lesions that activate cell death pathways. Sustained DNA damage induced by these drugs can provoke mutations in surviving non-cancerous cells, potentially increasing the risk of therapy-related cancers. Ligation of death receptors by ligands such as TRAIL, and subsequent activation of extrinsic apoptotic pathways, also provokes mutations. In this study, we show that executioner caspase activation of the apoptotic nuclease CAD/DFF40 is essential for TRAIL-induced mutations in surviving cells. As exposure to chemotherapy drugs also activates apoptotic caspases and presumably CAD, we hypothesized that these pathways may also contribute to the mutagenesis induced by conventional chemotherapy drugs, perhaps augmenting the mutations that arise from direct DNA damage provoked by these agents. Interestingly, vincristine-mediated mutations were caspase and CAD dependent. Executioner caspases accounted for some of the mutations caused by the topoisomerase poisons doxorubicin and SN38, but were dispensable for mutagenesis following treatment with cisplatin or temozolomide. These data highlight a non-apoptotic role of caspases in mutagenesis mediated by death receptor agonists, microtubule poisons and topoisomerase inhibitors, and provide further evidence for a potential carcinogenic consequence of sublethal apoptotic signaling stimulated by anticancer therapies.
引用
收藏
页码:e3062 / e3062
页数:13
相关论文
共 68 条
[1]   Mechanisms of therapy-related carcinogenesis [J].
Allan, JM ;
Lois, BT .
NATURE REVIEWS CANCER, 2005, 5 (12) :943-955
[2]   An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In Vivo [J].
Aubrey, Brandon J. ;
Kelly, Gemma L. ;
Kueh, Andrew J. ;
Brennan, Margs S. ;
O'Connor, Liam ;
Milla, Liz ;
Wilcox, Stephen ;
Tai, Lin ;
Strasser, Andreas ;
Herold, Marco J. .
CELL REPORTS, 2015, 10 (08) :1422-1432
[3]   Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies [J].
Azarova, Anna M. ;
Lyu, Yi Lisa ;
Lin, Chao-Po ;
Tsai, Yuan-Chin ;
Lau, Johnson Yiu-Nam ;
Wang, James C. ;
Liu, Leroy F. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (26) :11014-11019
[4]   Cellular Responses to Cisplatin-Induced DNA Damage [J].
Basu, Alakananda ;
Krishnamurthy, Soumya .
JOURNAL OF NUCLEIC ACIDS, 2010, 2010
[5]   Yeast techniques for modeling drugs targeting Bcl-2 and caspase family members [J].
Beaumont, T. E. ;
Shekhar, T. M. ;
Kaur, L. ;
Pantaki-Eimany, D. ;
Kvansakul, M. ;
Hawkins, C. J. .
CELL DEATH & DISEASE, 2013, 4 :e619-e619
[6]  
Betti CJ, 2001, CANCER RES, V61, P4550
[7]   Genetic Variation as a Modifier of Association Between Therapeutic Exposure and Subsequent Malignant Neoplasms in Cancer Survivors [J].
Bhatia, Smita .
CANCER, 2015, 121 (05) :648-663
[8]   New roles for old enzymes: killer caspases as the engine of cell behavior changes [J].
Connolly, Patrick F. ;
Jaeger, Richard ;
Fearnhead, Howard O. .
FRONTIERS IN PHYSIOLOGY, 2014, 5
[9]   Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy [J].
Czabotar, Peter E. ;
Lessene, Guillaume ;
Strasser, Andreas ;
Adams, Jerry M. .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2014, 15 (01) :49-63
[10]   Onto better TRAILs for cancer treatment [J].
de Miguel, D. ;
Lemke, J. ;
Anel, A. ;
Walczak, H. ;
Martinez-Lostao, L. .
CELL DEATH AND DIFFERENTIATION, 2016, 23 (05) :733-747